Regina Kunz

Regina Kunz

Auto-generated profile, based on publicly available information

Regina Kunz

11Basel Institute for Clinical Epidemiology, Hebelstrasse 10, CH 4031 Basel, Switzerland

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2012 in Chest
Verified
Journal Article
Closed access
JDJames D. Douketis
James D. Douketis
ASAlex C. Spyropoulos
Alex C. Spyropoulos
FSFrederick A. Spencer
Frederick A. Spencer
MMMichael Mayr
Michael Mayr
AJAmir K. Jaffer
Amir K. Jaffer
RKRegina Kunz
Regina Kunz

1 January 2008 in Annals of Internal Medicine
Verified
Journal Article
Closed access
PDF file
RKRegina Kunz
Regina Kunz
CFChris Friedrich
Chris Friedrich
MWMarcel Wolbers
Marcel Wolbers
JMJohannes F.E. Mann
Johannes F.E. Mann
Reduction of proteinuria is associated with delayed progression of chronic kidney disease. Reports suggest that angiotensin-receptor blockers (ARBs) reduce proteinuria, but results are variable. The relative effect of ARBs and angiotensin-converting enzyme (ACE) inhibitors, and their combined administration, remains uncertain. To establish the effect of ARBs versus placebo and alternative treatments, and the effect of combined treatment with ARBs and ACE inhibitors, on proteinuria. English-language studies in MEDLINE and the Cochrane Library Central Register of Controlled Trials (January 1990 to September 2006), reference lists, and expert contacts. Randomized trials of ARBs versus placebo, ACE inhibitors, calcium-channel blockers, or the combination of ARBs and ACE inhibitors in patients with or without diabetes and with microalbuminuria or proteinuria for whom data were available on urinary protein excretion at baseline and at 1 to 12 months. Two investigators independently searched and abstracted studies. Forty-nine studies involving 6181 participants reported results of 72 comparisons with 1 to 4 months of follow-up and 38 comparisons with 5 to 12 months of follow-up. The ARBs reduced proteinuria compared with placebo or calcium-channel blockers over 1 to 4 months (ratio of means, 0.57 [95% CI, 0.47 to 0.68] and 0.69 [CI, 0.62 to 0.77], respectively) and 5 to 12 months (ratio of means, 0.66 [CI, 0.63 to 0.69] and 0.62 [CI, 0.55 to 0.70], respectively). The ARBs and ACE inhibitors reduced proteinuria to a similar degree. The combination of ARBs and ACE inhibitors further reduced proteinuria more than either agent alone: The ratio of means for combination therapy versus ARBs was 0.76 (CI, 0.68 to 0.85) over 1 to 4 months and 0.75 (CI, 0.61 to 0.92) over 5 to 12 months; for combination therapy versus ACE inhibitors, the ratio of means was 0.78 (CI, 0.72 to 0.84) over 1 to 4 months and 0.82 (CI, 0.67 to 1.01) over 5 to 12 months. The antiproteinuric effect was consistent across subgroups. Most studies were small, varied in quality, and did not provide reliable data on adverse drug reactions. Proteinuria reduction is only a surrogate for important progression of renal failure. The ARBs reduce proteinuria, independent of the degree of proteinuria and of underlying disease. The magnitude of effect is similar regardless of whether the comparator is placebo or calcium-channel blocker. Reduction in proteinuria from ARBs and ACE inhibitors is similar, but their combination is more effective than either drug alone. Uncertainty concerning adverse effects and outcomes that are important to patients limits applicability of findings to clinical practice.

23 December 2009 in International Journal of Technology Assessment in Health Care
Verified
Journal Article
Closed access
PDF file
KLKristian Lampe
Kristian Lampe
MMMarjukka Mäkelä
Marjukka Mäkelä
MGMarcial Velasco Garrido
Marcial Velasco Garrido
HAHeidi Anttila
Heidi Anttila
IAIlona Autti-Rämö
Ilona Autti-Rämö
FKFinn Børlum Kristensen
Finn Børlum Kristensen
Objectives:The aim of this study was to develop and test a generic framework to enable international collaboration for producing and sharing results of health technology assessments (HTAs).Methods:Ten international teams constructed theHTA Core Model, dividing information contained in a comprehensive HTA into standardized pieces, theassessment elements. Each element contains a generic issue that is translated into practical research questions while performing an assessment. Elements were described in detail inelement cards. Two pilot assessments, designated asCore HTAswere also produced. The Model and Core HTAs were both validated. Guidance on the use of the HTA Core Model was compiled into aHandbook.Results: The HTA Core Model considers health technologies through nine domains. Two applications of the Model were developed, one for medical and surgical interventions and another for diagnostic technologies. Two Core HTAs were produced in parallel with developing the model, providing the first real-life testing of the Model and input for further development. The results of formal validation and public feedback were primarily positive. Development needs were also identified and considered. An online Handbook is available.Conclusions:The HTA Core Model is a novel approach to HTA. It enables effective international production and sharing of HTA results in a structured format. The face validity of the Model was confirmed during the project, but further testing and refining are needed to ensure optimal usefulness and user-friendliness. Core HTAs are intended to serve as a basis for local HTA reports. Core HTAs do not contain recommendations on technology use.

18 April 2007
Verified
Reference Entry
Closed access
RKRegina Kunz
Regina Kunz
GVGunn Elisabeth Vist
Gunn Elisabeth Vist
AOAndrew D Oxman
Andrew D Oxman

21 June 2012 in BMC Public Health
Verified
Journal Article
Open access
PDF file
JAJessica Anner
Jessica Anner
USUrban Schwegler
Urban Schwegler
RKRegina Kunz
Regina Kunz
BTBruno Trezzini
Bruno Trezzini
WBWout de Boer
Wout de Boer
Individuals who are sick and unable to work may receive wage replacement benefits from an insurer. For these provisions, a disability evaluation is required. This disability evaluation is criticised for lack of standardisation and transparency. The International Classification of Functioning, Disability and Health (ICF) was developed to express the situation of people with disability. We discuss potential benefits of the ICF to structure and phrase disability evaluation in the field of social insurance. We describe core features of disability evaluation of the ICF across countries. We address how and to what extent the ICF may be applied in disability evaluation.

12 May 2009 in BMC Medical Education
Verified
Journal Article
Open access
PDF file
RKRegina Kulier
Regina Kulier
SCSjors Fpj Coppus
Sjors Fpj Coppus
JZJavier Zamora
Javier Zamora
JHJulie Hadley
Julie Hadley
SMSadia Malick
Sadia Malick
Khalid KhanKhalid Khan
Khalid Khan
To evaluate the educational effects of a clinically integrated e-learning course for teaching basic evidence-based medicine (EBM) among postgraduates compared to a traditional lecture-based course of equivalent content.